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Scope
This guideline is aimed at providing healthcare professionals
with clear guidance on the management of patients with
diffuse large B-cell lymphoma (DLBCL). Disease confined
to specific extranodal sites, such as primary central nervous
system lymphoma, testicular lymphoma, primary mediasti-
nal large B-cell lymphoma, DLBCL of leg type, etc., is
beyond the scope of this guideline. It is not the intention
of this guideline to provide treatment recommendations for
all situations and clinicians are advised to make manage-
ment decisions taking into account individual patient
circumstances.
Methodology
The guideline group was selected to be representative of UK
experts in the assessment and treatment of DLBCL. Recom-
mendations are based on a systematic review of published
English language literature up to January 2015. MEDLINE
database was searched using the key words DLBCL, treat-
ment, radiotherapy and transplant. References from relevant
publications were also searched. Other published guidelines,
including the US National Comprehensive Cancer Network
(NCCN) and European Society for Medical Oncology guide-
lines, were also noted.
The writing group produced a draft guideline. Review of
the manuscript was performed by the British Committee for
Standards in Haematology (BCSH) by the Haemato-oncology
sounding board of the British Society for Haematology
(BSH). This consists of 50 or more members of the BSH
who have reviewed this Guidance and commented on its
content and applicability in the UK setting. It has also been
reviewed by a patient representative nominated by the Lym-
phoma Association, but the Association does not necessarily
approve or endorse the contents.
Recommendation grading
The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) nomenclature was used to evaluate
levels of evidence and to assess the strength of recommenda-
tions. The GRADE criteria are specified on the BCSH web
site. (http://www.bcshguidances.com/BCSH_PROCESS/42_
EVIDENCE_LEVELS_AND_GRADES_OF_RECOMMENDA
TION.html) and the GRADE working group website (http://
www.gradeworkinggroup.org/index.htm).
Background
This is a new evidence-based guideline on behalf of the
BCSH for the management of diffuse large B-cell non-Hodg-
kin lymphoma following a primary systematic review of the
evidence by the writing group using the methodology
described above.
Introduction
Diffuse large B-cell lymphoma is the most common non-
Hodgkin lymphoma (NHL), accounting for 30–40% of all
cases (Rodriguez-Abreu et al, 2007). Although most patients
are cured with 6–8 cycles of R-CHOP (rituximab with
cyclophosphamide, doxorubicin, vincristine and pred-
nisolone) chemotherapy, about 10–15% have primary
refractory disease and a further 20–30% relapse. The
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outlook for non-responders to R-CHOP is poor, though a
significant minority can be cured by high dose chemother-
apy (HDT) and haemopoietic stem cell transplantation.
There is an urgent need to improve outcome for patients
with DLBCL.
Baseline investigations and staging
Surgical excisional or incisional biopsy is strongly recom-
mended to obtain adequate tumour tissue for diagnosis.
Where this is not possible, core needle biopsies offer an
alternative but frequently yield small and insufficient sam-
ples for diagnostic confirmation. Fine needle aspiration
(FNA) is strongly discouraged. It is recommended that
all diagnostic material be reviewed by an expert
haematopathologist with clinicopathological correlation in
the multidisciplinary team (MDT) setting. All patients
should have baseline blood tests, including lactate dehydro-
genase (LDH) and screening for human immunodeficiency
virus (HIV), hepatitis B and hepatitis C. Left ventricular
function should be assessed by echocardiogram or multi-
gated acquisition scan in patients aged >65 years, and those
with a cardiac history. Fertility-preserving treatments, such
as sperm cryopreservation for male and referral to a fertility
specialist in female patients, should be considered for eligi-
ble patients.
Staging investigations
A full contrast enhanced staging computerized tomography
(CT) scan to include neck, chest, abdomen and pelvis should
be performed in all cases. Magnetic resonance imaging
(MRI)/CT imaging of the brain, orbits and sinuses will be
required for patients with CNS or craniofacial disease. Diag-
nostic lumbar puncture for cerebrospinal fluid (CSF) analy-
sis, including cytology and flow cytometry, is recommended
for patients with suspected CNS involvement. Intrathecal
methotrexate should be administered at the same time. A
staging positron emission tomography (PET)/CT is strongly
recommended as PET is more sensitive, especially for extran-
odal disease and improves staging accuracy and subsequent
response assessment (Meignan et al, 2009; Barrington et al,
2010, 2014; Quarles van Ufford et al, 2010; Cheson et al,
2014).The role of a routine staging bone marrow biopsy
(BMB) is under scrutiny as PET scanning demonstrates util-
ity for identifying bone marrow involvement (BMI). This is
usually seen as unifocal or multifocal uptake, with diffuse
activity being less common. In a recent meta-analysis involv-
ing 654 patients with aggressive NHL, the pooled sensitivity
and specificity for BMI was 89% and 100% respectively
(Adams et al, 2014). In DLBCL, some studies suggest that
PET is more sensitive for BMI than BMB (Berthet et al,
2013; Khan et al, 2013; Cerci et al, 2014), although low vol-
ume disease of <10–20% and discordant BMI with a low
grade lymphoma may be missed (Paone et al, 2009). As low
level (<10%) BMI with aggressive lymphoma is unlikely to
affect prognosis (Campbell et al, 2006), the value of a staging
BMB in DLBCL is currently a topic of hot debate. A BMB
may nevertheless be required for patients where the presence
of discordant BMI with low grade disease will affect
management.
Recommendations
• Wherever possible a surgical excisional or incisional
biopsy is strongly recommended to establish diagnosis.
Where this is not possible, a core needle biopsy is a less
preferred alternative (1A).
• All patients should have blood tests including LDH, HIV
and hepatitis B and hepatitis C virus screening (1A).
• Staging CT of neck, chest, abdomen, and pelvis should
be performed for all patients and imaging of the brain,
orbits and sinuses in selected patients (1A). Where pos-
sible, a staging PET/CT scan is recommended for all
patients (1B).
• Perform CSF for cytology and flow cytometry in all
patients with suspected CNS disease with administration
of intrathecal methotrexate at the same time (1A).
• Currently a staging bone marrow biopsy remains the
standard of care (1A). However, emerging evidence sug-
gests PET may be very valuable in assessing bone marrow
involvement in DLBCL though it may miss low level or
discordant disease (2B).
• All cases should be discussed at a Haemato-oncology
MDT meeting, with all diagnostic material being
reviewed by an expert haematopathologist (1A).
Prognostic factors
Clinical prognostic markers predicting adverse outcome
include advanced Ann Arbor stage, high International Prog-
nostic Index (IPI) and bulk disease with a tumour diameter
of >75 cm (The International Non-Hodgkin’s Lymphoma
Prognostic Factors Project 1993; Pfreundschuh et al, 2008a).
The revised IPI (Sehn et al, 2007) confirms the prognostic
significance of IPI in the R-CHOP era. The recently reported
enhanced NCCN-IPI (Zhou et al, 2014), appears to better
discriminate low and high risk groups. A high IPI also iden-
tifies patients at increased risk of CNS disease, which confers
poor prognosis.
Gene expression profiling (GEP) identifies distinct DLBCL
subtypes, originating from either germinal centre (GCB) or
activated B-cells (ABC) (Rosenwald et al, 2002). GEP of
ABC-type predicted an inferior outcome in the CHOP era
(Staudt, 2003). Although R-CHOP improves outcomes in
both subtypes, DLBCL of ABC-type continues to have a
worse prognosis (on univariate analysis) with a 40% 3-year
progression-free survival (PFS) compared to 75% for the
GCB-type (Lenz et al, 2008). Several immunohistochemistry
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(IHC) algorithms (Hans et al, 2004; Choi et al, 2009; Meyer
et al, 2011) have attempted to reproduce the GEP classifica-
tion with good correlation, but the resultant prognostic value
has been inconsistent in patients treated with rituximab in
addition to chemotherapy (Culpin et al, 2013).
MYC rearrangements, found in 5–10% of DLBCL by fluo-
rescent in-situ hybridization (FISH) (Obermann et al, 2009),
confer a poor prognosis in R-CHOP treated patients (Savage
et al, 2009; Barrans et al, 2010). Additionally, some patients
have BCL2 and/or BCL6 rearrangement (double- or triple-hit
lymphomas), also associated with a worse prognosis. Double-
hit lymphomas (DHLs) tend to be clinically aggressive with a
median survival of <12 months (Aukema et al, 2014; Li et al,
2014). Recent evidence suggests that the MYC partner gene is
important; translocation to non-immunoglobulin (Ig) part-
ner genes has little or no impact on survival (Pedersen et al,
2014). MYC and BCL2 protein overexpression as detected by
IHC is much more common, occurring in 20–30% of
DLBCL. This too confers an adverse prognosis with 5-year
survival of <30–40% with R-CHOP (Green et al, 2012; John-
son et al, 2012; Hu et al, 2013). Unlike DHLs, which are
usually of GCB-type, these tumours tend to be ABC-type.
TP53 mutation and TP53 over expression are associated with
decreased survival in both GCB and ABC tumours (Xu-Mon-
ette et al, 2012). The influence of other biological markers
(such as BCL2, BCL6, Ki-67) on survival in the rituximab
era is controversial.
Recommendations
• International Prognostic Index should be calculated for
all patients (1B).
• Where feasible, all cases of DLBCL should be tested for
MYC rearrangement by FISH and, if detected, further
testing should be performed for BCL2 and BCL6 rear-
rangements (1B).
Early stage disease
Patients with early stage DLBCL (stage IA or IIA disease) are
treated variably with either full course chemotherapy or
abbreviated chemotherapy with or without radiotherapy. In
the pre-rituximab era, the Southwest Oncology Group study
(SWOG 8736) showed that in localized aggressive NHL,
combined modality treatment with 3 cycles of CHOP fol-
lowed by involved field radiotherapy (IFRT) produced supe-
rior 5-year PFS (77% vs. 64%) and overall survival (OS)
(82% vs. 72%) compared to 8 cycles of CHOP (Miller et al,
1998). However, this difference was lost with longer follow-
up, suggesting that 3 cycles of chemotherapy may be inade-
quate for some patients with early stage disease. A British
Columbia Cancer agency (BCCA) study showed 5-year OS of
95% with 3 cycles of CHOP plus IFRT in young patients
with limited stage DLBCL and no adverse factors (Shenkier
et al, 2002), further establishing this as an effective strategy.
The Eastern Co-operative Oncology Group study (ECOG
1484) randomized complete responders after 8 cycles of
CHOP to receive IFRT (30 Gy) or to observation alone and
demonstrated an improvement in 6-year PFS with IFRT
(73% vs. 56%) (Horning et al, 2004).
The Groupe d’Etude des Lymphomes d’Adulte (GELA)
performed a randomized study of elderly patients with
limited stage disease and low risk IPI (GELA LNH 93-4).
There was no benefit from adding radiotherapy to 4 courses
of CHOP chemotherapy (Bonnet et al, 2007). In young
patients (<60 years) with limited stage disease, the GELA
LNH 93-1 study demonstrated a 5-year OS advantage for
the intensive ACVBP/MIA (doxorubicin, cyclophosphamide,
vindesine, bleomycin, prednisone/methotrexate, ifosfamide,
cytarabine) chemotherapy regimen over 3 cycles of CHOP
and 40 Gy IFRT(Reyes et al, 2005). However, this study
included patients with bulk disease (>10 cm) for whom 3
cycles of CHOP may be inadequate treatment. In a sub-
group analysis, no survival difference was found between
the two groups when comparing patients presenting with
non-bulky disease. Furthermore, in both the above studies,
there was a high loco-regional failure rate after radiotherapy
(21%).
The benefit of combined modality treatment has been
reported in the rituximab era. The SWOG 0014 study
reported a 4-year PFS of 88% and OS of 92% when ritux-
imab was added to 3 cycles of CHOP plus IFRT (Persky
et al, 2008). This represented an improvement over historical
data from the pre-rituximab era (4-year PFS and OS of 78%
and 88% respectively). The Mab-Thera International trial
(MInT) trial, reported benefit in both OS and EFS when
rituximab was added to CHOP-like chemotherapy in young
(<60 years) patients with low risk IPI disease (Pfreundschuh
et al, 2006). Most patients in this study had limited stage
disease and IFRT was given to bulky (>75 cm) and extran-
odal disease. The optimal number of R-CHOP cycles for
early stage disease is not clear. The German FLYER trial
(NCT00278421) is currently comparing 4 vs. 6 cycles of
R-CHOP for low IPI DLBCL patients.
Whilst there are no published randomized trials of radia-
tion therapy (RT) in the rituximab era to guide treatment
decisions, a single centre retrospective analysis demonstrated
an improvement in OS and PFS for patients receiving RT in
complete remission (CR) after 6–8 cycles of R-CHOP
chemotherapy. For patients with Stage I and II disease, the
5-year OS and PFS with RT were 92% and 82% whereas
without RT they were 73% and 68% respectively (Phan et al,
2010). Recently, by international consensus, the radiation
volume has been further reduced from IFRT to a new con-
cept of Involved Site Radiation Treatment (ISRT) (Illidge
et al, 2014).
In conclusion, RT decreases local recurrence rates. For
elderly patients and some younger patients with limited stage
disease, 3–4 cycles of R-CHOP followed by ISRT may be
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preferable, especially for sites where RT is well tolerated, e.g.
groin, axilla and neck. In contrast, a full course of 6–8 cycles
of R-CHOP may be preferable where RT might result in
debilitating late toxicity, such as xerostomia following paro-
tid treatment or increased breast cancer risk following medi-
astinal radiotherapy in younger women, albeit with the
acknowledgement that the increased number of cycles of R-
CHOP increases the risk of heart failure (Mulrooney et al,
2009).
Recommendations
• It is recommended that patients with non-bulky
(<75 cm) stage IA DLBCL presenting at sites associated
with low morbidity for radiotherapy (e.g. groin, neck or
axilla), be treated with 3–4 cycles of R-CHOP
chemotherapy followed by ISRT of 30 Gy (1B). Six cycles
of R-CHOP is an alternative and should be the preferred
option if disease involves a site where the acute and late
complications of RT are better avoided (1A).
• Patients with non-bulky stage IIA DLBCL should be
treated with 6 cycles of R-CHOP (1A).
• Patients with bulky stage IA/IIA DLBCL should be trea-
ted with 6 cycles of R-CHOP followed by ISRT of 30 Gy
to initial sites of bulk (1B).
Advanced stage disease
Patients with stage III or IV DLBCL or those with any stage
in the presence of B symptoms are treated as advanced stage
disease. Several studies have shown the benefit of adding
rituximab to CHOP, including the French GELA LNH 98-5
(Coiffier et al, 2002, 2010) and ECOG/CALGB 9703 (Haber-
mann et al, 2006). The German RICOVER-60 study (Pfre-
undschuh et al, 2008b) demonstrated improvements in
outcome following the addition of rituximab in elderly
patients; the MInT study showed the same for younger
patients with low IPI disease (Pfreundschuh et al, 2006).
The issue of dose density in the rituximab era was
addressed by comparing R-CHOP-14 with R-CHOP-21 by
the UK National Cancer Research Institute (NCRI) (Cun-
ningham et al, 2013) and the French GELA LNH03-6B
(Delarue et al, 2013) groups. Both studies showed no OS or
PFS difference between R-CHOP-14 and R-CHOP-21. R-
CHOP-21 therefore remains the standard treatment for
advanced stage DLBCL.
The French GELA LNH03-2B compared intensified
chemotherapy using 4 cycles of R-ACVBP followed by con-
solidation with 8 courses of R-CHOP chemotherapy in
young (<60 years) patients with low IPI disease (Recher et al,
2011). Whilst survival was better in the R-ACVBP arm,
results for the R-CHOP arm in this study were worse than
would be expected for this good risk group of patients. As
expected, the R-ACVBP regimen was also associated with
greater toxicity. Dose-adjusted EPOCH (etoposide, pred-
nisolone, vincristine, cyclophosphamide, doxorubicin) with
rituximab (DA-EPOCH-R) has also been reported to have
significant activity, especially in GCB-type DLBCL, in a Can-
cer and Leukemia Group B (CALGB) multicentre phase II
study (Wilson et al, 2008, 2012).
Patients with high-risk IPI DLBCL continue to have sub-
optimal outcomes in the rituximab era with predicted 5-year
survival of 50–55% with R-CHOP. A number of studies have
attempted to improve outcomes for high-risk patients using
either dose intensifying regimens or autologous stem cell
transplant (ASCT) in first remission. Four randomized trials
comparing R-chemotherapy with upfront HDT and ASCT
for high IPI disease were recently presented. Two trials
showed a PFS benefit for HDT and ASCT but no impact, at
present, on OS (US and Canadian intergroup SWOG S9704
trial; Italian Lymphoma Foundation DLCL04 trial)(Vitolo
et al, 2012; Stiff et al, 2013), whilst two trials failed to
demonstrate any benefit for HDT and ASCT (German
DSHNHL 2002-1 trial; GOELAMS 075 trial)(Dilhuydy et al,
2010; Schmitz et al, 2012). Upfront HDT and ASCT there-
fore remain investigational approaches and cannot be recom-
mended outside a clinical trial. Interestingly, the German
DSHNHL 2002-1 trial showed a 3-year event-free survival
(EFS) of 695% with R-CHOP plus etoposde (RCHOEP-14).
Although not a randomized comparison with R-CHOP, this
result in a large phase 3 randomized study represents a sig-
nificant improvement over R-CHOP results in patients with
high IPI disease. Early results from a prospective phase II
NCRI UK study using the dose intense R-CODOX-M/R-
IVAC (rituximab, cyclophosphamide, doxorubicin, vin-
cristine, methotrexate/rituximab, etoposide, ifosfamide,
cytarabine) regimen have also shown similarly encouraging
results in this setting (McMillan et al, 2013a).
Patients with DHLs have poor outcomes with R-CHOP
chemotherapy. Intensified chemotherapy regimens, such as
R-CODOX-M/R-IVAC or DA-EPOCH-R, are sometimes
used for treating Burkitt-like or grey zone lymphomas inter-
mediate between DLBCL and Burkitt lymphoma. Transplant
consolidation in first remission is also considered. At present
there is insufficient evidence to recommend any of these
strategies although retrospective studies suggest efficacy (Pet-
rich et al, 2014).
Patients with DLBCL at risk of CNS disease should be
considered for CNS prophylaxis. This is covered in a separate
BCSH guideline (McMillan et al, 2013b).
IFRT consolidation has traditionally been used in trial
protocols for bulky and extranodal disease. An exploratory
analysis of the prognostic significance of maximum tumour
(bulk) diameter (MTD) in young patients with good-prog-
nosis DLBCL was performed in the MInT study. The multi-
variate analysis showed MTD to be an adverse prognostic
factor after R-CHOP-like treatment, with 3-year OS of
980% for MTD <50 cm vs. 852% for MTD ≥100 cm
(Pfreundschuh et al, 2006). This study prompted the
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UNFOLDER study (NCT00278408) where patients with dis-
ease >75 cm were randomized to 36 Gy IFRT or no further
treatment. The study was prematurely closed by the Inde-
pendent Data Monitoring Committee in 2012 due to a
highly significant advantage in PFS in patients receiving RT.
In an amendment to the German RICOVER-60 trial, the
value of adding 36 Gy IFRT to initial sites of bulk
(>75 cm) or extranodal disease was evaluated. Patients
receiving IFRT had superior EFS, PFS and OS (Held et al,
2014). A large prospective randomized trial comparing
30 Gy with 40–45 Gy showed no difference between the two
arms (Lowry et al, 2011) Therefore, 30 Gy remains the rec-
ommended dose for consolidation therapy in patients with
responsive disease using ISRT (Illidge et al, 2014). Whether
radiotherapy can be avoided in patients achieving a PET-
defined complete metabolic response to chemotherapy
remains unknown and forms the basis of ongoing investiga-
tion. Patients with chemotherapy refractory disease require
higher doses of radiotherapy (45–55 Gy), depending on the
individual situation.
Response assessment
A negative PET scan at the end of treatment has a high nega-
tive predictive value (NPV) with a predicted 2-year PFS of
90–100%. However, the positive predictive value (PPV) is
lower, reported as 50–82% (Spaepen et al, 2001; Micallef et al,
2011; Pregno et al, 2012). Biopsy of a PET-positive lesion is
therefore advised prior to intensive salvage chemotherapy or,
alternatively, an interval scan after 3 months if clinical suspi-
cion of residual disease is low. The 5-Point Scale (Deauville
criteria) is recommended for response assessment (Barrington
et al, 2014; Cheson et al, 2014).
An interim PET scan during R-CHOP chemotherapy is
less predictive of outcome (Yang et al, 2011; Yoo et al, 2011;
Zinzani et al, 2011; Safar et al, 2012) than the end of treat-
ment scan, with some studies reporting no difference in out-
comes according to interim PET (Cashen et al, 2011;
Micallef et al, 2011; Pregno et al, 2012). Therefore, treatment
should not be altered solely on the basis of interim PET
unless there is clear evidence of progression. PET findings
should always be interpreted in relation to the clinical con-
text and expected prognosis.
Recommendations
• It is recommended that patients with advanced stage dis-
ease be treated with 6–8 cycles of R-CHOP-21. Variants
of this regimen include 6 cycles of R-CHOP-21 or R-
CHOP-14, each followed by 2 additional rituximab doses
(1A).
• There is no established standard of care for patients
with poor risk IPI disease. R-CHOP is often used but
RCHOEP-14 and RCODOX-M/R-IVAC are alternatives
(2C).
• CNS prophylaxis is recommended for selected patients
as per published BCSH guidelines (McMillan et al,
2013b) (2B).
• HDT and ASCT are not recommended in first remission
outside a clinical trial (1C)
• There is no accepted standard of care for patients with
double hit lymphoma. Treatment options include R-
CHOP with CNS prophylaxis, R-CHOEP-14, DA-
EPOCH-R or R-CODOX-M/R-IVAC. These patients may
be considered for a transplant consolidation in first
remission (2C).
• Where feasible, it is recommended that patients receive
ISRT to initial sites of bulk (>75 cm) and extranodal
disease after completing immunochemotherapy (1B).
• Outside of a clinical trial, identifying ABC/GCB subtypes
of DLBCL should not influence treatment decisions
(1C).
• The PPV of an interim PET scan is variable with insuffi-
cient evidence at present to change standard treatment
based on the result of interim PET-CT scan alone. A
routine interim PET scan is therefore not recommended
(1C).
• An end of treatment PET scan is strongly recommended
(1A).
• The PPV of a PET-positive lesion is variable; biopsy is
therefore advisable prior to second line treatment. Alter-
natively, consider an interval scan after 3 months if clin-
ical suspicion of residual disease is low (1B). ISRT to the
PET-positive lesion may be an option in selected cases
where biopsy is not possible or desirable (2C).
Relapsed/refractory disease in the transplant-
eligible patient
Confirmatory biopsy and restaging are strongly recom-
mended. Factors predicting prognosis at relapse include the
secondary age-adjusted IPI (sAAIPI) (Hamlin et al, 2003;
Lerner et al, 2007) and relapse within 1 year of R-CHOP
(Gisselbrecht et al, 2010). For those deemed fit for intensive
therapy, HDT followed by ASCT is recommended. The main
goal of salvage is to reduce disease burden and demonstrate
continued chemotherapy sensitivity prior to ASCT. Although
CR is not necessarily required, pre-transplant PET scan is
highly predictive of outcome following ASCT (Spaepen et al,
2003; Derenzini et al, 2008; Hoppe et al, 2009), with best
outcomes reported in those achieving a complete metabolic
remission (Johnston et al, 2008; Sauter et al, 2015). The
majority of favoured first-line salvage regimens include either
one or both of a platinum agent or ifosfamide, and there is
no clearly superior regimen (Gisselbrecht et al, 2010). Choice
should therefore be based upon consideration of side-effect
profiles, cost and lack of potential detrimental impact on the
ability to collect stem cells. Whilst addition of rituximab to
salvage regimens improves response rates in rituximab-na€ıve
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patients (Kewalramani et al, 2004; Vellenga et al, 2008), sim-
ilar data are lacking for those with prior exposure. Neverthe-
less, salvage with a regimen incorporating an anti-CD20
monoclonal antibody is generally recommended.
For patients who do not respond to first-line salvage, out-
comes are extremely poor with 1–3 year survival rates of
<10% (Ardeshna et al, 2005; Elstrom et al, 2010). Although
many clinicians attempt a second-line salvage regimen, the
ultimate curability of these patients is limited, and they
should be considered for clinical trials of novel agents.
In the pre-rituximab era, survival benefit was demon-
strated for patients consolidated with ASCT after achieving a
CR with salvage chemotherapy (Philip et al, 1995). Other
studies have reported that about a third of patients achieving
a partial remission (PR) also experience long-term disease-
free survival with ASCT, which is better than historical
results with chemotherapy alone (Kewalramani et al, 2000;
Vose et al, 2001; Rodriguez et al, 2004). Although response
rates to salvage are lower in the rituximab era, outcomes fol-
lowing ASCT appear similar in chemotherapy-sensitive
patients (Smith et al, 2011; Moore et al, 2012; Mounier et al,
2012), and recommendations regarding ASCT are therefore
the same.
The most commonly used conditioning regimen for ASCT
is BCNU, etoposide, cytarabine and melphalan (BEAM),
although other chemotherapy-based regimens appear to yield
broadly comparable outcomes (Stockerl-Goldstein et al,
1996). Chemotherapy-only regimens are generally preferred
due to the long-term toxicity of total body irradiation (TBI)-
based regimens (Armitage, 2003), with the possible addition
of localized radiation to sites of persistent disease (Biswas
et al, 2010). Incorporation of radioimmunotherapy in condi-
tioning remains investigational and routine use cannot be
recommended (Vose et al, 2013). No benefit has been shown
from using post-transplant rituximab maintenance (Gissel-
brecht et al, 2012). Finally, there is insufficient evidence for
tandem ASCT (Haioun et al, 2001).
The role of radiotherapy consolidation before or after
ASCT is unclear, with some studies showing benefit particu-
larly for those with large volume residual lesions (Hoppe
et al, 2009; Biswas et al, 2010), whilst others report no
impact (Friedberg et al, 2001; Wendland et al, 2007). Target-
ing therapy to patients with lesions showing persistent PET
activity following salvage might be a rational approach in the
absence of further data. The dose must be individualized, but
higher doses of up to 55 Gy may be required for cases pre-
senting with loco-regional problems or chemotherapy-refrac-
tory disease. No clear recommendations can be made on the
merits of pre- versus post-ASCT RT.
The prognosis of patients relapsing after ASCT is very
poor (Vose et al, 1993). Nevertheless a minority will respond
to salvage chemotherapy and may be considered for allo-
geneic stem cell transplant (alloSCT) (Rezvani et al, 2008;
Thomson et al, 2009; Sirvent et al, 2010; van Kampen et al,
2011; Bacher et al, 2012; Freytes et al, 2012). Time to relapse
following ASCT, and sensitivity to salvage chemotherapy are
the most important prognostic factors. AlloSCT is therefore
not recommended in those achieving less than a PR.
Defining a group of patients who should be considered
for alloSCT in preference to ASCT is challenging. Currently
there is no evidence that any specific high risk sub-groups
benefit from alloSCT versus ASCT. Overall survival outcomes
are similar for alloSCT and ASCT, with higher non-relapse
mortality (NRM) following alloSCT counterbalancing higher
relapse with ASCT (Aksentijevich et al, 2006; Lazarus et al,
2010). Although neither option can therefore be recom-
mended over the other, alloSCT using a conventional donor
is a reasonable clinical option for younger patients (age <40–
50 years) with high risk features, or in those in whom ASCT
is not possible due to inadequate stem cell dose.
The choice between myeloablative and reduced intensity
conditioning strategies for alloSCT is similarly challenging, as
comparative studies are flawed by differing selection criteria
(Rodriguez et al, 2006; Bacher et al, 2012; Hamadani et al,
2013). In general, myeloablative alloSCT may be considered
in patients <40 years of age who have not had a prior ASCT
with a reduced intensity alloSCT being preferred for all
others.
Recommendations
• Repeat biopsy is strongly recommended to confirm
relapse (1A).
• Transplant-eligible patients should receive intensive sal-
vage chemotherapy with a non-cross resistant regimen
followed by ASCT consolidation in those achieving CR
(1A).
• In those achieving a PR, second line salvage chemother-
apy can be given followed by ASCT if CR is achieved, or
consolidation by ASCT in PR can be considered (2B)
• Response assessment by PET scan prior to ASCT is
desirable (2B).
• Peri-transplant radiotherapy to sites of disease present-
ing particular loco-regional problems should be consid-
ered, particularly if residual PET-positive lesions are
detected following salvage (2B).
• There is no clearly defined group where alloSCT is
preferable to ASCT, but it may be an option for some
younger patients with high-risk disease, especially if
stem cell dose is inadequate for ASCT (2C).
• Selected patients relapsing post-ASCT may be considered
for further salvage and alloSCT (2B).
HIV-associated DLBCL
Development of HIV-associated DLBCL is related to older
age, lack of prior treatment with combined antiretroviral
therapy (cART) and low CD4 cell count (Engels et al, 2010).
Patients typically present with advanced stage disease and
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extranodal involvement, but survival is now approaching that
seen in HIV-negative patients (Coutinho et al, 2014). Treat-
ment is usually with either R-CHOP or infusional regimens,
such as R-EPOCH, with no randomized data to favour one
over the other. A recent multicentre retrospective UK study
reported excellent outcomes with R-CHOP (Coutinho et al,
2014). Although a previous phase III randomized study
reported increased rate of infectious complications with the
addition of rituximab to CHOP in patients with a CD4
count of <005 9 109/l of blood (Kaplan et al, 2005), subse-
quent phase 2 studies and a recent meta-analysis have con-
firmed the benefit of adding rituximab (Ribera et al, 2008;
Barta et al, 2012). Thus addition of rituximab to chemother-
apy is recommended for all patients with appropriate antimi-
crobial (co-trimoxazole, fluconazole and aciclovir) and
granulocyte colony-stimulating factor (G-CSF) prophylaxis.
Although there is some debate, in Europe it is common to
continue cART during chemotherapy, avoiding boosted pro-
tease inhibitors where possible (William et al, 2014). For a
detailed discussion of HIV-associated lymphomas please refer
to the British HIV Association guidelines (Bower et al,
2014).
Patients with relapsed disease should be treated similarly
to HIV-negative patients. Those with chemotherapy-sensitive
disease achieve similar outcomes with ASCT consolidation to
those of HIV-negative patients (Balsalobre et al, 2009; Diez-
Martin et al, 2009; Krishnan et al, 2010).
Recommendations
• Patients with HIV-associated DLBCL should be treated
with R-CHOP with concomitant cART (1A). R-EPOCH
is a suitable alternative (2B).
• All patients should receive antimicrobial (co-trimoxa-
zole, fluconazole and aciclovir) and granulocyte colony-
stimulating factor prophylaxis (1A).
• Patients with relapsed disease should be treated similarly
to HIV-negative patients, including using ASCT for
chemotherapy-sensitive relapse (1B).
Management of the elderly, frail or unfit
patient with DLBCL
The side effect profile of R-CHOP worsens with increasing
comorbidity, functional disability (van de Schans et al, 2012;
Boslooper et al, 2014; Merli et al, 2014; Wieringa et al, 2014)
and advancing age (Kobayashi et al, 2011; Lin et al, 2012).
Consequently, in practice only a minority of patients
>80 years are treated with full dose R-CHOP. Their outcome,
especially following the attainment of CR, is comparable to
that of patients aged less than 80 years (Varga et al, 2014)
making it imperative to undertake a careful assessment of fit-
ness for R-CHOP before considering less toxic and potentially
less effective alternatives. There is no uniformly accepted age
cut-off to define an ‘elderly’ patient as it is applied variably to
those aged >60, >65 or >70 years in different studies, with
patients >80 years being classified as ‘very elderly’. Tools such
as the comprehensive geriatric assessment (CGA) (Olivieri
et al, 2012; Spina et al, 2012) or the simpler Charlson comor-
bidity index (Kobayashi, et al 2011, Lin et al, 2012) may assist
physician judgment in identifying those patients who are suit-
able for R-CHOP. Using this approach, two prospective stud-
ies of CGA-modified R-CHOP in patients aged over 70 years
reported 5-year OS of 46% for all patients (Olivieri et al,
2012) and 76%, 53%, 29% for fit, unfit and frail patients
respectively (Spina et al, 2012). Treatment-related mortality
in both studies was relatively low at 14–17%.
As demonstrated by the DSHNHL group, steroid pre-
treatment of patients with a WHO performance status of >2
may render them suitable for standard R-CHOP (Pfreund-
schuh et al, 2004; Pfreundschuh, 2010). Primary G-CSF pro-
phylaxis in patients >65 years with poor performance/
nutritional status or significant comorbidity reduces the risk
of febrile neutropenia and related morbidity with R-CHOP
and, in line with European Organisation for Research and
Treatment of Cancer guidelines, routine use is recommended
to improve treatment tolerance (Repetto et al, 2003).
Modified regimens have been evaluated in patients unsuit-
able for full-dose R-CHOP. The French GELA group
reported 2-year OS and PFS of 59% and 47% respectively
using R-mini-CHOP in patients aged >80 years, predomi-
nantly with advanced stage disease and without significant
comorbidity or lymphoma-related organ impairment (Peyr-
ade et al, 2011). The treatment-related mortality was 21%.
Two other retrospective studies corroborate the use of dose
reduced R-CHOP in patients aged 60 to >80 years (Shin
et al, 2012; Aoki et al, 2013). Co-morbidity may necessitate
replacement of vincristine (peripheral neuropathy), pred-
nisolone (diabetes mellitus) or doxorubicin (cardiac disease
or risk factors) (Spina et al, 2012) by an alternative drug.
Phase ll data support consideration of R-GCVP (rituximab,
gemcitabine, vincristine, prednisolone) (Fields et al, 2014) or
R-COMP14 (Biweekly rituximab, cyclophosphamide, vin-
cristine, non-pegylated liposome-encapsulated doxorubicin,
prednisone) (Corazzelli et al, 2011) in patients unfit for
doxorubicin.
Recommendations
• There is no uniformly accepted age cut-off to define an
‘elderly’ patient. Treatment decisions should be based on
assessment of fitness/frailty and co-morbidities rather
than age alone (1A).
• Patients considered fit for intense treatment should be
treated with standard R-CHOP as this produces best
outcomes (1B).
• Modified R-CHOP with dosage and/or individual drug
adjustments should be considered for those unfit for
standard treatment (2C).
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• Patients with impaired performance status (WHO > 2)
at presentation, should be considered for a steroid pre-
phase prior to assessing fitness for standard or modified
R-CHOP (2B).
• Primary G-CSF prophylaxis is recommended for patients
aged >65 years, frail patients and those with significant
comorbidities (1A).
Follow-up
Patients who achieve a CR following treatment should be fol-
lowed up on a 3–4 monthly basis for up to 2 years. Outside
a clinical trial, there is no role for routine surveillance scans
during post-treatment follow-up and patients should be
assessed clinically. The risk of relapse beyond 2 years is
<10% (Larouche et al, 2010; Vose et al, 2010). It is therefore
reasonable to discharge patients back to their primary care
physician at that stage with advice and support.
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